Table 4 Pooled incidences of TBD among IMID patients treated with different classes of DMARDs
DMARD | Pooled incidences of TBD/100,000py (% IC 95%) | Test for overall effect |
|---|---|---|
All TNFi Etanercept Adalimumab Infliximab Golimumab Certolizumab | 0.84 (0.7–0.97) 0.39 (0.24–0.54) 0.85 (0.62–1.07) 0.98 (0.60–1.36) 0.47 (0.28–0.66) 0.19 (0.02–0.36) | p < 0.00001 p < 0.00001 p < 0.00001 p < 0.00001 p < 0.00001 p = 0.03 |
All non-TNFi bDMARDs Rituximab Abatacept Tocilizumab | 0.35 (0.25–0.46) 0.72 (-0.63-2.07) 0.32 (0.21–0.43) 0.32 (0.01–0.63) | p < 0.00001 p = 0.3 p < 0.00001 p < 0.00001 |
All tsDMARDs | 0.18 (0.09–0.27) | p < 0.00001 |
All csDMARDs | 0.20 (0.05–0.34) | p = 0.009 |